UNITED
      STATES


**SECURITIES
      AND EXCHANGE COMMISSION**


**WASHINGTON,
      D.C. 20549**





**FORM
      10-QSB**





(Mark
      One)





x
            QUARTERLY
                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





For
      the
      quarterly period ended September 30, 2007





OR





 ̈
            TRANSITION
                REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





Commission
      file number 33-19598-D





**VYTA
      CORP**


(Exact
      name of small business issuer as specified in its charter)





Nevada
            
            84-0992908(State
                or other jurisdiction of
            
            (I.R.S.
                employerincorporation
                or organization)
            
            identification
                number)





370
      17th Street,
      Suite 3640


Denver,
      Colorado 80202


(Address
      of principal executive offices)





Issuer’s
      telephone number, including area code: (303) 592-1010





Check
      whether the issuer (1) has filed all reports required to be filed by Section
      13(a) or 15(d) of the Securities Exchange Act of 1934 during the past 12 months
      (or for such shorter period that the registrant was required to file such
      reports), and (2) has been subject to such filing requirements for the past
      90
      days. Yes­ xNo
­­ ̈





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes
 ̈
      No x





State
      the
      number of shares outstanding of each of the issuer’s classes of common equity,
      as of the latest practicable date:






As
        of
        November 16, 2007 there were 32,879,845 shares of the registrant’s sole class of
        common shares outstanding.
 
 Transitional
        Small Business Disclosure Format Yes  ̈
        No x







**PART
                I – FINANCIAL INFORMATION**Item
                1. Financial Statements (Unaudited)
            
            PageCondensed
                Consolidated Balance Sheet –September 30,
                2007
            
            F-1Condensed
                Consolidated Statements of Operations - Three months
                ended September 30, 2007 and 2006
            
            F-2Condensed
                Consolidated Statements of Comprehensive Loss – Three
                months ended September 30, 2007 and 2006
            
            F-3Condensed
                Consolidated Statement of Changes in Shareholders’
                Equity –Three months ended September 30, 2007
            
            F-4Condensed
                Consolidated Statements of Cash Flows – Three months
                ended September 30, 2007 and 2006
            
            F-5Notes
                to Condensed Consolidated Financial
                Statements
            
            F-6Item
                2. Management’s Discussion and
                Analysis
            
            1Item
                3. Controls and Procedures
            
            3Item
                3A(T) Controls and Procedures
            
            3**PART
                II – OTHER INFORMATION**Item
                1. Legal Proceedings –*Not
                Applicable*
            
            4Item
                2. Unregistered Sales of Equity Securities and Use
                of
                Proceeds
            
            4Item
                3. Defaults Upon Senior Securities – *Not
                Applicable*
            
            4Item
                4. Submission of Matters to a Vote of Security Holders
–
                *Not Applicable*
            
            4Item
                5. Other Information – *Not
                Applicable*
            
            4Item
                6. Exhibits
            
            5SIGNATURES
            
            6


*Table
          of Contents*


**PART
      I – FINANCIAL INFORMATION**








**Item
      1. Financial Statements**








VYTA
      CORP
      AND SUBSIDIARIES


Condensed
      Consolidated Balance Sheet


September
      30, 2007


(Unaudited)





AssetsCurrent
                assets:Cash
                and cash equivalents
            
            $
            129,055Prepaid
                expenses and other
            
            
            2,026Total
                current assets
            
            
            131,081Property
                and equipment:Office
                equipment and furniture
            
            
            67,107Less
                accumulated depreciation
            
            
            (62,823
            )4,284Other
                assets:Deposits
                and other
            
            
            19,562Notes
                and advances receivable, unconsolidated investee (Note 2)
            
            
            267,249Investment
                in unconsolidated investee (Note 3)
            
            
            199,899486,710Total
                assets
            
            $
            622,075


Liabilities
                and Shareholders’ EquityCurrent
                liabilities:Accounts
                payable
            
            $
            80,123Accounts
                payable, officer (Note 4)
            
            
            4,110Accrued
                expenses
            
            
            7,062Total
                liabilities (all current)
            
            
            91,295Commitments
                and contingencies (Note 6)Shareholders’
                equity:Preferred
                stock; $0.0001 par value; 5,000,000 shares authorized; Series A,
                8%;
                deemed par value $1.00 per share; 500,000 shares issued and outstanding;
                liquidation preference of $522,602
            
            
            522,602Common
                stock; $0.0001 par value; 200,000,000 shares authorized; 32,879,845
                shares issued and outstanding
            
            
            3,288Additional
                paid-in capital
            
            
            30,898,357Accumulated
                other comprehensive income
            
            
            130,787Accumulated
                deficit
            
            
            (31,024,254
            )Total
                shareholders’ equity
            
            
            530,780Total
                liabilities and shareholders’ equity
            
            $
            622,075See
                notes to condensed consolidated financial statements.


F-1
 *Table
            of Contents*




VYTA
      CORP
      AND SUBSIDIARIES


Condensed
      Consolidated Statements of Operations


Three
      Months Ended September 30, 2007 and 2006


(Unaudited)








2007
            
            
            2006General
                and administrative expense
            
            $
            (145,748
            )
            
            $
            (275,414
            )Loss
                from operations
            
            
            (145,748
            )
            
            
            (275,414
            )Other
                income (expense):Equity
                losses of unconsolidated investees (Note 3)
            
            
            (380,825
            )
            
            
            (267,558
            )(380,825
            )
            
            
            (267,558
            )Net
                loss
            
            
            (526,573
            )
            
            
            (542,972
            )Accumulated
                dividends on Series A preferred stock (Note 5)
            
            
            (9,452
            )
            
            
            -Net
                loss applicable to common Shareholders
            
            $
            (536,025
            )
            
            $
            (542,972
            )Net
                loss per common share, basic and diluted (Note 1)
            
            $
            (0.02
            )
            
            $
            (0.02
            )Weighted
                average number of common shares outstanding (Note 1)
            
            
            32,060,062
            
            
            
            22,643,512





See
      notes
      to condensed consolidated financial statements.


F-2
 *Table
            of Contents*






VYTA
      CORP
      AND SUBSIDIARIES


Condensed
      Consolidated Statements of Comprehensive Loss


Three
      Months Ended September 30, 2007 and 2006




2007
            
            
            2006Net
                loss
            
            $
            (526,573
            )
            
            $
            (542,972
            )Change
                in unrealized gain on Securities
            
            
            -
            
            
            
            35Change
                in foreign currency translation adjustment
            
            
            9,244
            
            
            
            -Comprehensive
                loss
            
            $
            (517,329
            )
            
            $
            (542,937
            )





See
      notes
      to condensed consolidated financial statements.


F-3
 *Table
          of Contents*


VYTA
      CORP
      AND SUBSIDIARIES


Condensed
      Consolidated Statements of Changes in Shareholders’ Equity


Three
      Months Ended September 30, 2007


(Unaudited)





Additional
            
            
            Accumulated
                other
            
            
            
            
            
            TotalPreferred
                stock
            
            
            Common
                stock
            
            
            paid
                in
            
            
            comprehensive
            
            
            Accumulated
            
            
            shareholders’Shares
            
            
            Amount
            
            
            Shares
            
            
            Amount
            
            
            capital
            
            
            income
            
            
            deficit
            
            
            equityBalances,
                July 1, 2007
            
            
            500,000
            
            
            $
            513,150
            
            
            
            31,349,845
            
            
            $
            3,135
            
            
            $
            30,678,462
            
            
            $
            121,543
            
            
            $
            (30,497,681
            )
            
            $
            818,609Common
                stock issued for cash
            
            
            -
            
            
            
            -
            
            
            
            1,530,000
            
            
            
            153
            
            
            
            229,347
            
            
            
            -
            
            
            
            -
            
            
            
            229,500Net
                loss
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            (526,573
            )
            
            
            (526,573
            )Accumulated dividends
                on Series A preferred stock
            
            
            -
            
            
            
            9,452
            
            
            
            -
            
            
            
            -
            
            
            
            (9,452
            )
            
            
            -
            
            
            
            -
            
            
            
            -Change
                in foreign currency translation adjustment
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            9,244
            
            
            
            -
            
            
            
            9,244Balances,
                September 30, 2007
            
            
            500,000
            
            
            $
            522,602
            
            
            
            32,879,845
            
            
            $
            3,288
            
            
            $
            30,898,357
            
            
            $
            130,787
            
            
            $
            (31,024,254
            )
            
            $
            530,780





See
      notes
      to condensed consolidated financial statements.


F-4
 *Table
          of Contents*


VYTA
      CORP
      AND SUBSIDIARIES


Condensed
      Consolidated Statements of Cash Flows


Three
      Months Ended September 30, 2007 and 2006


(Unaudited)








2007
            
            
            2006Cash
                flows from operating activities:Net
                loss
            
            $
            (526,573
            )
            
            $
            (542,972
            )Adjustments
                to reconcile net loss to net cash used in operating
                activities:Amortization
                expense
            
            
            -
            
            
            
            117,689Depreciation
                expense
            
            
            1,153
            
            
            
            1,346Equity
                losses of unconsolidated investees
            
            
            380,825
            
            
            
            267,558Changes
                in operating assets and liabilities:Decrease
                in prepaid expenses and other
            
            
            653
            
            
            
            15,143(Decrease)increase
                in accounts payable and accrued expenses
            
            
            (17,174
            )
            
            
            11,722Total
                adjustments
            
            
            365,457
            
            
            
            413,458Net
                cash used in operating activities
            
            
            (161,116
            )
            
            
            (129,514
            )Cash
                flows from investing activities:Increase
                in notes and advances receivable, unconsolidated investee
            
            
            (294,031
            )
            
            
            (191,000
            )Net
                cash used in investing activities
            
            
            (294,031
            )
            
            
            (191,000
            )Cash
                flows from financing activities:Common
                stock issued for cash
            
            
            229,500
            
            
            
            -Proceeds
                applied to preferred stock and warrant purchase
            
            
            -
            
            
            
            140,000Net
                cash provided by financing activities
            
            
            229,500
            
            
            
            140,000Net decrease
                in cash and cash equivalents
            
            
            (225,647
            )
            
            
            (180,514
            )Cash
                and cash equivalents, beginning
            
            
            354,702
            
            
            
            192,359Cash
                and cash equivalents, ending
            
            $
            129,055
            
            
            $
            11,845





See
      notes
      to condensed consolidated financial statements.


F-5
 *Table
          of Contents*




**VYTA
        CORP AND SUBSIDIARIES**
 Notes
        to
        Condensed Consolidated Financial Statements
 Three
        Months Ended September 30, 2007 and 2006
 (Unaudited)


**1.
      BASIS OF PRESENTATION, MANAGEMENT'S PLANS, AND SUMMARY OF
      SIGNIFICANT ACCOUNTING POLICIES:**





**BASIS
      OF PRESENTATION:**





Presentation
      of Interim Information:





The
      accompanying condensed consolidated financial statements include the accounts
      of
      Vyta Corp, a Nevada corporation (the Company), its wholly-owned subsidiaries,
      NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS), and
      ExypnoTech, LLC (ET LLC), a Colorado limited liability company. NCOS and ET
      LLC
      had no revenues or operations in 2007 and 2006. The Company has two investments
      which are accounted for using the equity method of accounting. These equity
      method investments consist of ExypnoTech, GmbH (EPT) and BioAgra, LLC (BioAgra)
      (Note 3). The Company's equity investees, EPT and BioAgra, operate in two
      segments, the RFID industry and the animal feed industry, respectfully. All
      significant intercompany accounts and transactions have been eliminated in
      consolidation.





In
      the
      opinion of the management of the Company, the accompanying unaudited condensed
      consolidated financial statements include all material adjustments, including
      all normal and recurring adjustments, considered necessary to present fairly
      the
      financial position and operating results of the Company for the periods
      presented. The financial statements and notes are presented as permitted by
      Form
      10-QSB, and do not contain certain information included in the Company’s Annual
      Report on Form 10-KSB for the fiscal year ended June 30, 2007. It is the
      Company’s opinion that when the interim financial statements are read in
      conjunction with the June 30, 2007 Annual Report on Form 10-KSB, the disclosures
      are adequate to make the information presented not misleading. Interim results
      are not necessarily indicative of results for a full year or any future
      period.





**MANAGEMENT’S
      PLANS:**





In
      the
      Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2007,
      the Report of the Independent Registered Public Accounting Firm includes an
      explanatory paragraph that describes substantial doubt about the Company’s
      ability to continue as a going concern. The Company’s interim financial
      statements for the three months ended September 30, 2007 have been prepared
      on a
      going concern basis, which contemplates the realization of assets and the
      settlement of liabilities and commitments in the normal course of business.
      The
      Company reported a net loss of $526,573 and a net loss applicable to common
      stockholders of $536,025 for the three months ended September 30, 2007, and
      an accumulated deficit of $31,024,254 as of September 30, 2007. The Company
      has
      not recognized any revenues from its business operations.





During
      the 2008 fiscal year, the Company intends to continue its efforts to assist
      BioAgra with the continuing development of its sales, nationally and
      internationally in other animal feed markets, such as the equine and the swine
      markets. The Company intends to continue to raise funds to support the efforts
      through the sale of its equity securities.





These
      factors raise substantial doubt about the Company’s ability to continue as a
      going concern. The financial statements do not contain any adjustments relating
      to the recoverability and classification of assets or the amounts and
      classification of liabilities that might be necessary should the Company be
      unable to continue as a going concern.





Currently,
      the Company does not have a revolving loan agreement with any financial
      institution, nor can the Company provide any assurance it will be able to enter
      into any such agreement in the future, or be able to raise funds through a
      further issuance of debt or equity in the Company.


F-6
 *Table
          of Contents*






**VYTA
      CORP AND SUBSIDIARIES**


Notes
      to
      Condensed Consolidated Financial Statements


Three
      Months Ended September 30, 2007 and 2006


(Unaudited)


**SUMMARY
      OF SIGNIFICANT ACCOUNTING POLICIES:**





**STOCK-BASED
      COMPENSATION:**





Beginning
      July 1, 2006, the Company adopted the provisions of and accounts for stock-based
      compensation in accordance with the Statement of Financial Accounting standards
      No. 123 – revised 2004 (“SFAS 123R”), *Share-Based Payment*, which
      replaced Statement of Financial Accounting Standards No. 123 (“SFAS 123”),
*Accounting for Stock-based Compensation*, and supersedes APB Opinion No.
      25 (“APB 25”), *Accounting for Stock Issued to Employees*. Under the fair
      value recognition provisions of this statement, stock-based compensation cost
      is
      measured at the grant date based on the fair value of the award and is
      recognized as expense on a straight-line basis over the requisite service
      period, which is the vesting period. The Company elected the
      modified-prospective method, under which prior periods are not revised for
      comparative purposes. The valuation provisions of SFAS 123R apply to new grants
      and to grants that were outstanding as of the effective date and are
      subsequently modified. All options granted prior to the adoption of SFAS 123R
      and outstanding during the periods presented were fully-vested. The Company
      did
      not grant any options during the three months ended September 30, 2007 and
      2006
      (Note 5).





**LOSS
      PER SHARE:**





Basic
      loss per share of common stock is computed based on the average number of common
      shares outstanding during the year. Stock options and warrants are not
      considered in the calculation, as the impact of the potential common shares
      (14,859,844 shares at September 30, 2007 and 6,519,469 shares at September
      30,
      2006) would be to decrease loss per share (anti-dilutive). Therefore, diluted
      loss per share is equivalent to basic loss per share.





**RECENTLY ADOPTED
      ACCOUNTING PRONOUNCEMENTS:**





In
        February 2006, the Financial Accounting Standards Board ("FASB") issued SFAS
        155, *Accounting for Certain Hybrid Financial Instruments.*SFAS 155
        allows financial instruments that contain an embedded derivative and that
        otherwise would require bifurcation to be accounted  for as a whole on a
        fair value basis, at the holder’s election. SFAS 155 also clarifies and amends
        certain other provisions of SFAS 133 and SFAS 140. SFAS 155 is effective
        for the
        Company for all financial instruments issued or acquired after the beginning
        of
        July 1, 2007. The adoption of SFAS 155 did not have an impact on the Company’s
        financial statements.




The
      Company adopted FASB Interpretation No. 48, *"Accounting for Uncertainty in
      Income Taxes"* ("FIN 48") on July 1, 2007. The Company did not identify any
      controversial tax positions taken on open tax years and did not have any
      unrecognized tax benefits, and there was no effect on the Company's financial
      condition or results of operations as a result of implementing FIN 48. The
      Company files income tax returns in the U.S. federal jurisdiction and various
      state jurisdictions. The Company is no longer subject to U.S. federal tax
      examinations for years before 2003. State jurisdictions that remain subject
      to
      examination range from 2002 to 2006. The Company does not believe there will
      be
      any material changes in its unrecognized tax positions over the next 12 months.
      The Company's policy is to recognize interest and penalties accrued on
      unrecognized tax benefits as a component of income tax expense. As of the date
      of adoption of FIN 48, the Company did not have any accrued interest or
      penalties associated with any unrecognized tax benefits and not interest expense
      or penalties were recognized during the quarter.





**2.
      NOTES AND ADVANCES RECEIVABLE – UNCONSOLIDATED INVESTEE:**





During
      the year ended June 30, 2006, the Company loaned $1,686,570 to BioAgra through
      a
      series of secured, 7.5% promissory notes, which were due from June 30 through
      October 31, 2006. On June 26, 2006, the Company agreed to combine all of the
      promissory notes and accrued interest of $40,257 into a $1,726,827 secured,
      7.5%
      promissory note with payments to be made monthly starting October 31, 2006,
      through October 31, 2007. The funds were loaned to facilitate BioAgra's
      completion of its first production line and to support operations. The
      promissory note is collateralized by all BioAgra assets. Additionally, the
      promissory note is to be paid in full prior to any distributions being made
      to
      the members of the joint venture. During the year ended June 30, 2007, the
      note
      was reduced by $1,371,269, which represents the excess of the BioAgra losses
      recognized by the Company over the adjusted equity method basis of the Company’s
      investment in BioAgra.


F-7
 *Table
          of Contents*




**VYTA
        CORP AND SUBSIDIARIES**
 Notes
        to
        Condensed Consolidated Financial Statements
 Three
        Months Ended September 30, 2007 and 2006
 (Unaudited)


During
      the year ended June 30, 2007, the Company advanced an additional $1,182,784
      to
      BioAgra. During
      the three months ended September 30, 2007, the Company advanced an additional
      $284,135 to BioAgra at 7.5% interest. In October 2007, the Company
      executed a second, 7.5% promissory note for $1,182,784 with BioAgra with the
      same terms as the note above, but the note did not provide for scheduled
      payments. The Company has classified these notes receivable as non-current
      assets on the balance sheet and is not accruing interest on these notes
      receivable, as they are currently in default and non-performing.






**3.
      INVESTMENTS IN UNCONSOLIDATED INVESTEES:**





**INVESTMENT
      IN EPT:**





At
      September 30, 2007, the Company's investment in EPT is $199,899. The Company's
      proportionate (loss) income was $(13,670) and $37,348 for the three months
      ended September 30, 2007 and 2006, respectively. Financial information of EPT
      as
      of September 30, 2007, and for the three months ended September 30, 2007 and
      2006 is as follows:





September
                30, 2007Assets:Current
                assets
            
            $
            1,161,406Equipment
            
            
            3,067Total
                assets
            
            $
            1,164,473Liabilities
                and members’ equity:Current
                liabilities
            
            $
            883,036Members’
                equity
            
            
            281,437Total
                liabilities and members’ equity
            
            $
            1,164,473


F-8
 *Table
            of Contents*




**VYTA
        CORP AND SUBSIDIARIES**
 Notes
        to
        Condensed Consolidated Financial Statements
 Three
        Months Ended September 30, 2007 and 2006
 (Unaudited)


Three
                Months Ended
            
            
            Three
                Months EndedSeptember
                30,2007
            
            
            September
                30, 2006Revenues(1)
            
            $
            828,632
            
            
            $
            568,551Expenses(2)
            
            
            (856,590
            )
            
            
            (492,331
            )Net
                (loss) income
            
            $
            (27,958
            )
            
            $
            76,220








(1)
      Revenues include $825,689 and $568,551 of sales to the 51% owner of EPT for
      the
      three months ended September 30, 2007 and 2006, respectively.


(2)
      Expenses include $96,671 and $38,278 of charges paid to the 51% owner of EPT
      for
      the three months ended September 30, 2007 and 2006, respectively.




**INVESTMENT
      IN BIOAGRA**





The
      Company has a 50% equity interest in the joint venture, BioAgra, which
      manufactures and plans to sell a beta glucan product, YBG-2000 also known as
      AgraStim(TM),
      which can be used as a replacement for hormone growth steroids and antibiotics
      in animal feed products such as poultry feed. As of September 30, 2007, BioAgra
      (a development stage company) has completed construction of a production line;
      however BioAgra has not yet recognized any significant revenues from product
      sales.





The
      terms
      of the joint venture provide for the Company to share in 50% of joint venture
      net income, if any, or net losses. The Company is accounting for its investment
      in BioAgra as an equity method investment. Net losses incurred by BioAgra have
      exceeded the underlying equity attributed to BioAgra’s other joint venture
      investor. As a result, the excess of the losses attributable to the other joint
      venture investor have been charged to the Company. Since September 30, 2006
      and
      through September 30, 2007, the carrying value of the Company’s investment in
      BioAgra was $0. BioAgra losses for the three months ended September 30, 2007
      and
      2006 were $367,155, and $304,905, respectively. Losses of $367,155
      and $197,589, respectively, were applied to reduce the value of the
      note receivables from BioAgra.





Financial
      information of BioAgra as of September 30, 2007, for the three months ended
      September 30, 2007 and 2006, is as follows:





September
                30, 2007Assets:Current
                assets
            
            $
            183,310Land,
                building and equipment, net (2)
            
            
            2,608,104Total
                assets
            
            $
            2,791,414Liabilities
                and members’ deficiency:Current
                liabilities(1)
            
            $
            3,588,270Obligation
                under capital lease(2)
            
            
            941,540Total
                liabilities
            
            
            4,529,810Members’
                deficiency
            
            
            (1,738,396
            )Total
                liabilities and members’ deficiency
            
            $
            2,791,414





(1)
      Includes $3,183,747 owed to the Company.


F-9
 *Table
          of Contents*




**VYTA
        CORP AND SUBSIDIARIES**
 Notes
        to
        Condensed Consolidated Financial Statements
 Three
        Months Ended September 30, 2007 and 2006
 (Unaudited)


(2)
      BioAgra leases land and a building under a ten-year lease expiring in February
      2015, which requires a monthly lease payment of $12,000.





Three
                Months Ended
            
            
            Three
                Months EndedSeptember
                30, 2007
            
            
            September
                30, 2006Revenues
            
            $
            20,327
            
            
            $
            31,642Expenses
            
            
            (387,482
            )
            
            
            (336,547
            )Net
                loss
            
            $
            (367,155
            )
            
            $
            (304,905
            )




**4.
      ACCOUNTS PAYABLE, OFFICER:**





At
      September 30, 2007, the Company owes its President $4,110 for amounts advanced
      to the Company or for reimbursements. This amount is unsecured, non-interest
      bearing and due on demand.





**5.
      SHAREHOLDERS' EQUITY:**





***PREFERRED
      STOCK:***





In
      February 2007, the Company sold 500,000 shares of Series A nonconvertible
      preferred stock for $500,000 cash to Arizcan Properties, Ltd. (Arizcan). Arizcan
      had advanced the funds to the Company, prior to the issuance of the shares.
      The
      shares provide that when voting as a single class, the shares have the votes
      and
      the voting power that at all times is greater by 1% than the combined votes
      and
      voting power of all other classes of securities entitled to vote on any matter.
      As a result of the issuance, Arizcan acquired approximately 51% of the voting
      power of the Company. The Company has a right, solely at its discretion, to
      redeem the shares in 2017 at 130% of the deemed par value.





The
      holder of the Series A is entitled to a dividend equal to 8% per annum of the
      deemed par value ($1.00 per share). Accumulated dividends for the period
      from Series A issuance (February 2007) through September 30, 2007, were $22,602
      ($9,452 for the three months ended September 30, 2007), which have been recorded
      as an increase to net loss per common shareholder. Also, the holder is
      entitled to a liquidation preference of the deemed par value for each
      outstanding share and any accrued but unpaid dividends upon the liquidation
      of
      the Company.





***COMMON
      STOCK:***





Between
      July 2007 and September 2007, the Company issued an aggregate of 1,530,000
      shares of its restricted common stock for $229,500 cash. The shares were sold
      for $0.15 per share (based upon an approximately 55% discount from the closing
      market price at the time of sale, ranging from $0.39-$0.40 per share on the
      dates of the transactions).





***STOCK
      OPTIONS:***





The
      Company has two stock option plans which permit the grant of shares to attract,
      retain and motivate employees, directors and consultants of up to 2,863,000
      shares of common stock. Options are generally granted with an exercise price
      equal to the Company's market price of its common stock on the date of the
      grant
      and with vesting rates, as determined by the Board of Directors. All options
      outstanding at July 1, 2007 and September 30, 2007 are fully-vested and
      exercisable. The Company did not grant any options during the three months
      ended
      September 30, 2007 and 2006. The aggregate intrinsic value of outstanding
      fully-vested options as of September 30, 2007 was approximately
      $155,000.


F-10
 *Table
          of Contents*




**VYTA
        CORP AND SUBSIDIARIES**
 Notes
        to
        Condensed Consolidated Financial Statements
 Three
        Months Ended September 30, 2007 and 2006
 (Unaudited)


A
      summary
      of the stock option activity for the three months ended September 30, 2007
      is as
      follows:





Shares
                Under
              Option
            
            
            Weighted
              Average
              Exercise
              Price
            
            
            Weighed
              Average
              Remaining
              Contractual
              LifeOutstanding
                at July 1, 2007
            
            
            2,748,127
            
            
            $
            3.00
            
            
            3.89
                yearsGranted
            
            
            -
            
            
            
            -
            
            
            
            -Exercised
            
            
            -
            
            
            
            -
            
            
            
            -Expired
            
            
            -
            
            
            
            -
            
            
            
            -Outstanding
                at September 30, 2007
            
            
            2,748,127
            
            
            $
            3.00
            
            
            3.62
                yearsExercisable
                at September 30, 2007
            
            
            2,748,127
            
            
            $
            3.00
            
            
            3.62
                years




**6.
      COMMITMENTS AND CONTINGENCIES**





**LITIGATION:**





*Financing
      Agreement Suit:*





In
      connection with a financing obtained in October 2000, the Company filed various
      actions in the United States District Court for the District of Colorado
      against, among others, Harvest Court, LLC, Southridge Capital Investments,
      LLC,
      Daniel Pickett, Patricia Singer and Thomson Kernaghan, Ltd. for violations
      of
      federal and state securities laws, conspiracy, aiding and abetting and common
      law fraud among other claims. As a result of various procedural rulings, in
      January 2002, the United States District Court for the District of Colorado
      transferred the case to the United States District Court for the Southern
      District of New York, New York City, New York.





In
      this
      litigation, Harvest Court, LLC filed counterclaims against the Company and
      certain officers and former board members of the Company, and a number of
      unrelated third parties. The counterclaims allege violations of federal
      securities laws and other laws. Harvest Court, LLC is seeking various forms
      of
      relief including compensatory and punitive damages. Responsive pleadings have
      been filed and the litigation is currently in the discovery stage.





In
      May
      2001, Harvest Court, LLC filed suit against the Company in the Supreme Court
      of
      the State of New York, County of New York. The suit alleges that the Company
      breached an October 20, 2000 Stock Purchase Agreement, by not issuing 370,945
      free trading shares of the Company's common stock in connection with the reset
      provisions of the Purchase Agreement due on the second reset date and
      approximately 225,012 shares due in connection with the third reset date.
      Harvest Court, LLC is seeking the delivery of such shares or damages in the
      alternative. In August 2001, the Supreme Court of the State of New York, County
      of New York issued a preliminary injunction ordering the Company to reserve
      and
      not transfer the shares allegedly due to Harvest Court, LLC. The Company has
      filed counterclaims seeking various forms of relief against Harvest Court,
      LLC.
      Discovery has been completed in these cases and a trial date is expected to
      be
      set by the Court.





The
      Company intends to vigorously prosecute all litigation and does not believe
      the
      outcome of the litigation will have a material adverse effect on the financial
      condition, results of operations or liquidity of the Company. However, it is
      too
      early at this time to determine the ultimate outcome of these
      matters.


F-11
 *Table
          of Contents*


**Item
      2. Management’s Discussion and Analysis**





Certain
      statements contained in this Form 10-QSB contain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995
      and
      involve risks and uncertainties that could cause actual results to differ
      materially from the results, financial or otherwise, or other expectations
      described in such forward-looking statements. Any forward-looking statement
      or
      statements speak only as of the date on which such statements were made, and
      the
      Company undertakes no obligation to update any forward-looking statement to
      reflect events or circumstances after the date on which such statements are
      made
      or reflect the occurrence of unanticipated events. Therefore, forward-looking
      statements should not be relied upon as prediction of actual future
      results.





The
      independent registered public accounting firm’s report on the Company’s
      consolidated financial statements as of June 30, 2007, and for each of the
      years
      in the two-year period then ended, includes a “going concern” explanatory
      paragraph, that describes substantial doubt about the Company’s ability to
      continue as a going concern. Management’s plans in regard to the factors
      prompting the explanatory paragraph are discussed below and also in Note 1
      to
      the unaudited quarterly financial statements.





**Plan
      of Operations**






At
      September 30, 2007, we had cash on hand of $129,055. We intend to use our cash
      funds to continue to support operations. We intend to continue to develop the
      business opportunity presented by our investment in an
      unconsolidated investee, BioAgra and the AgriStim product. The development
      of the business opportunity includes continued marketing efforts and product
      testing over the next twelve months.





In
      the
      continuance of our business operations we do not intend to purchase or sale
      any
      significant assets and we do not expect a significant change in the number
      of
      employees of the Company.





We
      are
      dependent on raising additional equity and/or, debt to fund any negotiated
      settlements with our outstanding creditors and meet our ongoing operating
      expenses. There is no assurance that we will be able to raise the necessary
      equity and/or debt that we will need to be able to negotiate acceptable
      settlements with our outstanding creditors or fund our ongoing operating
      expenses. We cannot make any assurances that we will be able to raise funds
      through such activities.





**Results
      of Operations**






During
      the three months ended September 30, 2007 and 2006, we did not have any revenues
      from operations.





General
      and administrative expenses during the three months ended September 30, 2007
      were $145,748 compared to $275,414 for the three months ended September 30,
      2006. The decrease of $129,666 is mainly attributable to a $115,620 decrease
      in
      consulting expenses and a $10,272 decrease in payroll expenses.





During
      the three months ended September 30, 2007, we recognized a net loss of $526,573
      compared to a net loss of $542,972 during the three months ended September
      30,
      2006. The $16,399 decrease is primarily a result of the $129,666 decrease in
      general and administrative expenses, discussed above. This decrease is offset
      by
      the $113,267 increase in equity losses of unconsolidated investees.





We
      recorded a net loss applicable to common shareholders of $536,025 during the
      three months ended September 30, 2007 compared to $542,972 during the three
      months ended September 30, 2006. The increase of $16,858 was a result of the
      $9,452 increase in the accumulated dividends recognized in connection with
      the
      outstanding Series A Preferred Stock and the increase in losses of the
      unconsolidated equity investees. These increases are offset by the decrease
      in
      general and administrative expenses of $129,666.


1
 *Table
          of Contents*


**Liquidity
      and Financial Condition**






Net
      cash
      used in operating activities during the three months ended September 30, 2007
      was $161,116, compared to net cash used in operating activities during the
      three
      months ended September 30, 2006 of $129,514. During the three months ended
      September 30, 2007, the net cash used represented a net loss of $526,573,
      adjusted for certain non-cash items consisting of depreciation expense of $1,153
      and equity in losses of unconsolidated investee of $380,825.





During
      the three months ended September 30, 2006, the net cash used represented a
      net
      loss of $542,972, adjusted certain non-cash items consisting of the amortization
      and depreciation expense of $119,035 and equity in losses of unconsolidated
      investees of $267,558.





During
      the three months ended September 30, 2007, we raised $229,500 cash through
      the
      sale of 1,530,000 shares of its restricted common stock.





During
      the three months ended September 30, 2006, we received $140,000 cash, which
      was
      a prepayment on a series of preferred stock, which was issued in March
      2007.





During
      the year ended June 30, 2006, the Company loaned $1,686,570 to BioAgra through
      a
      series of secured, 7.5% promissory notes, which were due over the period from
      June 30 through October 31, 2006. On June 26, 2006, the Company agreed to
      combine all of the promissory notes and accrued interest of $40,257 into a
      $1,726,827 secured, 7.5% promissory note with payments to be made monthly
      starting October 31, 2006, through October 31, 2007. The funds were loaned
      to
      facilitate BioAgra's completion of its first production line and to support
      operations. The promissory note is collateralized by all BioAgra assets.
      Additionally, the promissory note is to be paid in full prior to any
      distributions being made to the members of the joint venture. During the year
      ended June 30, 2007, the note was reduced by $1,478,584, which represents the
      excess of the BioAgra losses recognized by the Company over the adjusted basis
      of the Company’s equity investment in BioAgra remaining at June 30,
      2007.





During
      the year ended June 30, 2007, the Company advanced an additional $1,182,784
      to
      BioAgra. In October 2007, the Company executed a second, 7.5% promissory note
      for $1,182,784 with BioAgra with the same terms as the note above, but the
      note
      did not provide for scheduled payments. The Company has classified these notes
      receivable as non-current assets on the balance sheet and is not accruing
      interest on these notes receivable, as they are currently in default and
      non-performing.





During
      the fourth quarter of the year ended June 30, 2007, the Company made a decision
      to impair the value of note receivable. This decision was based on factors
      including the Company’s evaluation of past and current operating results,
      failure of BioAgra to make scheduled payments and the Company’s continuing
      support of the operational efforts of BioAgra. The Company also considered
      the
      fair value of BioAgra’s assets and liabilities in making the decision. As a
      result of this decision, the Company recorded an impairment charge of $1,198,000
      in the fourth quarter ended June 30, 2007.





During
      the three months ended September 30, 2007, the Company has advanced an
      additional $284,135 to BioAgra under the same terms as the promissory note,
      described above.





During
      the 2008 fiscal year, we intend to continue our efforts to aid BioAgra with
      the
      continuing development of its sales, nationally and internationally in other
      animal feed markets, such as the equine and the swine markets. In addition,
      in
      January 2007, we signed a six-month technology agreement to permit a prospective
      licensee the opportunity to conduct a market survey relating to its NCOSTM
technology. The agreement was not renewed. However, we believe that if the
      market survey is favorable the technology agreement may mature into a royalty
      paying commercial license the terms and conditions of which are under
      negotiation with the perspective licensee.





To
      the
      extent our operations are not sufficient to fund our capital requirements,
      we
      may enter into a revolving loan agreement with financial institutions or attempt
      to raise capital through the sale of additional capital stock or through the
      issuance of debt. At the present time we do not have a revolving loan agreement
      with any financial institution nor can we provide any assurance that we will
      be
      able to enter into any such agreement in the future or be able to raise funds
      through the further issuance of debt or equity.


2
 *Table
          of Contents*


**Recently Adopted
      Accounting Pronouncements**






In
      February 2006, the Financial Accounting Standards Board (“FASB”) issued SFAS
      155, Accounting for Certain Hybrid Financial Instruments. SFAS 155 allows
      financial instruments that contain an embedded derivative and that otherwise
      would require bifunction to be accounted for as a whole on a fair value
      basis, at the holder’s election. SFAS 155 also clarifies and amends certain
      other provisions of SFAS 133 and SFAS 140. SFAS 155 is effective for us for
      all
      financial instruments issued or acquired after July 1, 2007. The adoption of
      SFAS 155 did not have an impact on the Company’s financial
      statements.





In
      June
      2006, the FASB issued Interpretation No. 48, *Accounting for Uncertainty in
      Income Taxes - An Interpretation of FASB Statement No. 109*, (FIN 48). FIN
      48 clarifies the accounting for uncertainty in income taxes recognized in an
      enterprise's financial statements in accordance with FASB Statement No. 109,
      Accounting for Income Taxes. FIN 48 also prescribes a recognition threshold
      and
      measurement attribute for the financial statement recognition and measurement
      of
      a tax position taken or expected to be taken in a tax return that results in
      a
      tax benefit. Additionally, FIN 48 provides guidance on de-recognition, income
      statement classification of interest and penalties, accounting in interim
      periods, disclosure, and transition. We adopted this statement effective for
      our
      fiscal year beginning July 1 2007. We have described the impact of adopting
      FIN
      48 in our condensed consolidated financial statements in Note 1, Recently Issued
      Accounting Pronouncements.





**Item
      3. CONTROLS AND PROCEDURES**





As
      of the
      end of the period covered by this Quarterly Report on Form 10-QSB, the Company
      carried out an evaluation, under the supervision and with the participation
      of
      the Company's President and Chief Financial Officer, of the effectiveness of
      the
      design and operation of the Company's disclosure controls and procedures (as
      such term is defined in Rules 13a-14(c) and 15d-14(c) under the Securities
      Exchange Act of 1934, as amended (the "Exchange Act"). Based upon such
      evaluation, such officers have concluded that the Company's disclosure controls
      and procedures are effective as of the end of the period covered by this
      quarterly report on Form 10-QSB in alerting them, on a timely basis, to material
      information relating to the Company required to be included in the Company's
      periodic SEC filings and to ensure that information required to be disclosed
      in
      the Company's periodic SEC filings is accumulated and communicated to the
      Company's management, including its President and Chief Financial Officer,
      to
      allow timely decisions regarding required disclosure.





There
      was
      no change to the Company's internal controls over financial reporting during
      the
      fiscal quarter ended September 30, 2007 that has materially affected, or is
      reasonably likely to materially affect, the Company's internal controls over
      financial reporting.


3
 *Table
          of Contents*


PART
      II –
OTHER INFORMATION





**Item
      1. Legal Proceedings****– No
      Change.**





**Item
      2**. **Unregistered Sales of Equity Securities and
      Use of Proceeds**





The
      Company made the following unregistered sales of its securities from July 1,
      2007 to September 30, 2007.





**DATE
                OF**
              **SALE**
            
            **TITLE
                OF SECURITIES**
            
            **NO.
                OF**
              **SHARES**
            
            
            **CONSIDERATION**
            
            **CLASS
                OF PURCHASER**7/9/07
            
            Common
                Stock
            
            
            180,000
            
            
            $
            27,000
            
            Affiliate8/1/07
            
            Common
                Stock
            
            
            150,000
            
            
            $
            22,500
            
            Affiliate8/2/07
            
            Common
                Stock
            
            
            150,000
            
            
            $
            22,500
            
            Affiliate8/7/07
            
            Common
                Stock
            
            
            300,000
            
            
            $
            45,000
            
            Affiliate8/8/07
            
            Common
                Stock
            
            
            150,000
            
            
            $
            22,500
            
            Affiliate8/17/07
            
            Common
                Stock
            
            
            150,000
            
            
            $
            22,500
            
            Affiliate9/28/07
            
            Common
                Stock
            
            
            450,000
            
            
            $
            67,500
            
            Affiliate





Exemption
      From Registration Claimed





All
      of
      the sales by the Company of its unregistered securities were made by the Company
      in reliance upon Section 4(2) of the Act. The affiliate listed above that
      purchased the unregistered securities was known to the Company and its
      management, through pre-existing business relationships. The purchaser was
      provided access to all material information, which they requested, and all
      information necessary to verify such information and was afforded access to
      management of the Company in connection with the purchases. The purchaser of
      the
      unregistered securities acquired such securities for investment and not with
      a
      view toward distribution, acknowledging such intent to the Company. All
      certificates or agreements representing such securities that were issued
      contained restrictive legends, prohibiting further transfer of the certificates
      or agreements representing such securities, without such securities either
      being
      first registered or otherwise exempt from registration in any further resale
      or
      disposition.





**Item
      3. Defaults Upon Senior Securities –
None.**





**Item
      4. Submission of Matters to a Vote of Security Holders –
None.**





**Item
      5. Other Information – None.**


4
 *Table
          of Contents*


**Item
      6. EXHIBITS**






**Exhibits.**
      The following is a complete list of exhibits filed as part of this Form 10-QSB.
      Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601
      of
      Regulation S-B.





Exhibit
      31.1 Certification of Chief Executive Officer pursuant
      to Section
      302 of the Sarbanes-Oxley Act





Exhibit
      32.1 Certification of Principal Executive
      Officer pursuant
      to Section 906 of the Sarbanes-Oxley Act


5
 *Table
          of Contents*


**SIGNATURES**





In
      accordance with the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.





**VYTA
                CORP****(Registrant)**Date:
                November 19, 2007
            
            /s/
                Paul H. MetzingerPaul
                H. Metzinger,President
                & CEO & Principal Accounting Officer(Principle
                Executive Officer)










6